Abhimanyu Verma
Known title: Chief Technology OfficerCIK: 0002114540
Associated companies
Transaction History
| SOPH | ▼ Sell | Open Market | 5,000 | $44K | 8/24/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 5,000 | $41K | 8/19/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 5,000 | $38K | 8/7/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 5,000 | $35K | 8/4/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 5,285 | $27K | 7/6/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 6,944 | $38K | 6/25/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 1,030 | $5K | 4/7/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 2,519 | $12K | 4/6/2026 | View on chart |
| SOPH | ▲ Buy | Grant | 82,136 | $0 | 4/2/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
SOPHiA GENETICS Shares Rise 7% Amid Questions on Momentum
Shares of SOPHiA GENETICS climbed 7% in early trading, pushing the stock toward the upper end of its 52‑week range. The move comes with an RSI of 55.5, indicating moderate momentum, and the stock remains above the $4.85 support level that has been tested 13 times. Analysts keep a target of $9.75, but the recent gain raises questions about how long the upward trend can continue.
SOPHiA GENETICS Shares Rise 7% Amid Questions on Momentum. Shares of SOPHiA GENETICS climbed 7% in early trading, pushing the stock toward the upper end of its 52‑week range. The move comes with an RSI of 55.5, indicating moderate momentum, and the stock remains above the $4.85 support level that has been tested 13 times. Analysts keep a target of $9.75, but the recent gain raises questions about how long the upward trend can continue.